Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO CERV4 pembrolizumab in high-grade HPV-related vulvar and cervical lesions
2023-504035-40-00Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN) and human papillomavirus infection, sponsored by Policlinico Gemelli. Primary endpoint: Histologic clearance of cervical HSIL. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
cervical intraepithelial neoplasia (CIN)vulvar intraepithelial neoplasia (VIN)human papillomavirus infection
Beyond the preview
Go deeper on 2023-504035-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504035-40-00.